Stock analysts at StockNews.com initiated coverage on shares of Organovo (NASDAQ:ONVO – Get Rating) in a research note issued on Tuesday. The firm set a “sell” rating on the medical research company’s stock.
Organovo Stock Up 2.5 %
Shares of ONVO stock opened at $1.67 on Tuesday. Organovo has a fifty-two week low of $1.37 and a fifty-two week high of $4.67. The stock has a market cap of $14.55 million, a P/E ratio of -1.22 and a beta of 1.01. The business has a fifty day simple moving average of $1.58 and a 200-day simple moving average of $2.10.
Organovo (NASDAQ:ONVO – Get Rating) last posted its quarterly earnings data on Thursday, November 10th. The medical research company reported ($0.38) EPS for the quarter. The company had revenue of $0.08 million during the quarter.
Institutional Trading of Organovo
Organovo Holdings, Inc is engaged in the development of bioprinted human tissues that emulate human biology and disease. Its three-dimensional human tissue platform is enabled by its proprietary NovoGen Bioprinters and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
- Get a free copy of the StockNews.com research report on Organovo (ONVO)
- Is the Northrop Grumman Selloff an Opportunity?
- Is the Worst Behind for Under Armor Stock with a New CEO?
- Analysts Like The Fit Of Skechers USA
- What Does Microsoft’s Investment in ChatGBT Mean for MSFT Stock?
- Can We Trust The Rally In The S&P 500
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.